CASI Pharmaceuticals, Inc.
CASINASDAQHealthcare
$0.15
+$0.00(+3.08%)
Market Cap$2331664
P/E Ratio—
52W High$3.09
52W Low$0.135
CASI Pharmaceuticals, Inc. (CASI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CASI · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 14, 2025EPS Actual
-$0.67
Est. -$0.40 · -67.5%
Revenue
$0.00B
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 14, 2025
After Market Close
▼ Miss EPS
CASI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Apr 29, 2026 | -$0.36 | — | — | — | — | — |
| ◌ Q1 FY2026 | Mar 30, 2026 | -$0.36 | — | — | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.40 | -$0.67 | -67.5% | $0.00B | — | — |
| ▼ Q3 FY2025 | Aug 29, 2025 | -$0.47 | -$0.86 | -83.0% | $0.00B | $0.01B | -33.5% |
| ▼ Q2 FY2025 | May 16, 2025 | -$0.61 | -$0.69 | -13.1% | $0.01B | $0.01B | -0.9% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.60 | -$0.79 | -31.7% | $0.01B | $0.01B | +80.6% |
| ▲ Q4 FY2024 | Nov 15, 2024 | -$0.62 | -$0.55 | +11.3% | $0.01B | $0.00B | +70.9% |
| ▲ Q3 FY2024 | Aug 16, 2024 | -$0.63 | -$0.52 | +17.5% | $0.00B | $0.00B | -10.2% |
Q2 FY2026
Apr 29, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 30, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.67
EPS Est.
-$0.40
EPS Surpr.
-67.5%
Revenue
$0.00B
Q3 FY2025
Aug 29, 2025Miss
EPS Actual
-$0.86
EPS Est.
-$0.47
EPS Surpr.
-83.0%
Revenue
$0.00B
Q2 FY2025
May 16, 2025Miss
EPS Actual
-$0.69
EPS Est.
-$0.61
EPS Surpr.
-13.1%
Revenue
$0.01B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.79
EPS Est.
-$0.60
EPS Surpr.
-31.7%
Revenue
$0.01B
Q4 FY2024
Nov 15, 2024Beat
EPS Actual
-$0.55
EPS Est.
-$0.62
EPS Surpr.
+11.3%
Revenue
$0.01B
Q3 FY2024
Aug 16, 2024Beat
EPS Actual
-$0.52
EPS Est.
-$0.63
EPS Surpr.
+17.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q2 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q1 FY2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q4 FY2025 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q3 FY2025 | $-0.40 | $-0.40 | $-0.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 14, 2025 | -67.5% | $1.34 | $1.26 | -5.97% |
| ▼ Q3 FY2025 | Aug 29, 2025 | -83.0% | $2.44 | $2.31 | -5.33% |
| ▼ Q2 FY2025 | May 16, 2025 | -13.1% | $1.81 | $1.94 | +7.18% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -31.7% | $2.15 | $2.16 | +0.47% |
| ▲ Q4 FY2024 | Nov 15, 2024 | +11.3% | $5.88 | $5.33 | -9.35% |
| ▲ Q3 FY2024 | Aug 16, 2024 | +17.5% | $6.56 | $6.56 | +0.00% |
| ▼ Q2 FY2024 | May 14, 2024 | -1320.0% | $2.57 | $3.17 | +23.35% |
| ▼ Q1 FY2024 | Mar 28, 2024 | -20.8% | $3.00 | $3.61 | +20.33% |
Q4 FY2025-5.97%
Report Date
Nov 14, 2025
EPS Beat/Miss
-67.5%
Price Before
$1.34
Price After
$1.26
Q3 FY2025-5.33%
Report Date
Aug 29, 2025
EPS Beat/Miss
-83.0%
Price Before
$2.44
Price After
$2.31
Q2 FY2025+7.18%
Report Date
May 16, 2025
EPS Beat/Miss
-13.1%
Price Before
$1.81
Price After
$1.94
Q1 FY2025+0.47%
Report Date
Mar 31, 2025
EPS Beat/Miss
-31.7%
Price Before
$2.15
Price After
$2.16
Q4 FY2024-9.35%
Report Date
Nov 15, 2024
EPS Beat/Miss
+11.3%
Price Before
$5.88
Price After
$5.33
Q3 FY2024+0.00%
Report Date
Aug 16, 2024
EPS Beat/Miss
+17.5%
Price Before
$6.56
Price After
$6.56
Q2 FY2024+23.35%
Report Date
May 14, 2024
EPS Beat/Miss
-1320.0%
Price Before
$2.57
Price After
$3.17
Q1 FY2024+20.33%
Report Date
Mar 28, 2024
EPS Beat/Miss
-20.8%
Price Before
$3.00
Price After
$3.61
Avg Beat Reaction-4.67%
Avg Miss Reaction+6.67%
Beat Rate2 / 8 quarters
Largest Move+23.35% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CASI ends December
CASI Pharmaceuticals, Inc. (CASI) most recently reported earnings on November 14, 2025 for Q4 FY2025, posting EPS of $-0.67 — missing the analyst consensus of $-0.40 by -67.5%. The next CASI earnings date is expected around September 1, 2026.
Each quarter, investors track CASI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CASI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CASI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CASI earnings · 5 questionsCASI Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CASI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CASI historically reports after market close (AMC).
CASI earnings datewhen is CASI earningsCASI next earnings datewhen does CASI report earningsCASI earnings calendar
▸ Source: FMP · CASI Pharmaceuticals, Inc. SEC filings · US GAAP · CASI Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026